Market openNon-fractional

Tango Therapeutics/TNGX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Tango Therapeutics

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

Ticker

TNGX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

140

TNGX Metrics

BasicAdvanced
$891M
Market cap
-
P/E ratio
-$1.12
EPS
0.79
Beta
-
Dividend rate
$891M
0.79
8.227
8.03
13.677
14.458
-19.47%
-45.41%
22.303
3.36
3.36
-6.805
49.72%
-11.13%
58.61%
-7.48%

What the Analysts think about TNGX

Analyst Ratings

Majority rating from 8 analysts.
Buy

TNGX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-592.18% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$6.4M
18.52%
Net income
-$38M
23.45%
Profit margin
-592.18%
4.16%

TNGX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.90%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.23
-$0.23
-$0.32
-$0.35
-
Expected
-$0.34
-$0.35
-$0.28
-$0.31
-$0.34
Surprise
-31.55%
-33.33%
15.21%
11.90%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Tango Therapeutics stock?

Tango Therapeutics (TNGX) has a market cap of $891M as of July 05, 2024.

What is the P/E ratio for Tango Therapeutics stock?

The price to earnings (P/E) ratio for Tango Therapeutics (TNGX) stock is 0 as of July 05, 2024.

Does Tango Therapeutics stock pay dividends?

No, Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Tango Therapeutics dividend payment date?

Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders.

What is the beta indicator for Tango Therapeutics?

Tango Therapeutics (TNGX) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Tango Therapeutics stock

Buy or sell Tango Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing